Kanglaite Breast
kanglaite
An injectable microemulsion of a purified oil extracted from the seeds of the traditional Chinese medicinal herb Coix lacryma-jobi (Job’s tears), with potential antineoplastic activity. Although the exact mechanism of action is unknown, kanglaite exhibits an antineoplastic effect, potentially via interfering with the cell cycle and halting tumor cells in the G2/M phase, which may eventually inhibit mitosis and proliferation of cancer cells. Check for active clinical trials using this agent. (NCI Thesaurus)
Kanglaite (also known as Coix lacryma-jobi)
UPDATE January 2010 (from Michael McCulloch, LAc,MPH, PhD from Pine Street Foundation sent this:
There is a trial open in 9 states:
(http://clinicaltrials.gov/ct2/show/NCT00733850?term=kanglaite&rank=1) Ann’s NOTE: This trial ended in 2014/2015 with a statement that FDA would take a next step. ClinicalTrials.gov lists 8 studies, all in the USA have been ‘terminated’. Some are being done in China. (as of April 2020) Under the herb name we found 73 studies – mostly (unsurprisingly) in cell culture, called in vitro.
Excerpted from:
Ralph W. Moss, Ph.D. Weekly CancerDecisions.com
Newsletter #43 07/10/02
“FDA Approves Test of Traditional Chinese Medicine for Cancer
The US Food and Drug Administration (FDA) has approved a clinical trial of Kanglaite, a drug derived from an herb used in Traditional Chinese Medicine (TCM). The source of the drug is a tropical Asian grass called coix** (pronounced “coy”) or Job’s tears (lacryma-jobi), which is related to corn (maize).
The stalks of the coix plant contain white beadlike grains that, in addition to being eaten, are sometimes used to make necklaces.”
** I was perusing your website and noticed a little “misnomer” or incorrect writing of plant names. The plant species involved in the “Kangleite” research is a grass species with botanical name of Coix lacryma-jobi.
This is the Latin binomial name used by botanists worldwide, and it is the only stable and universally recognizable name for this plant. The common or vernacular names are often confusing or misleading; use them, but also use the botanical Latin name at the same time.
The name of the genus here is Coix. The name of the species is Coix lacryma-jobi. When written this way, these names should be italicized or underlined. There are at least four other species in the genus Coix. I thought this might help a bit.**
Bill B.
http://www.kanglaite-usa.com/, or
contact them at:
Kanglaite USA
Phone: 801-364-8904
Fax: 801-531-6558
Email: [email protected]
Metronomic Dosing: Chemotherapy
Giannoula Klement of Sunnybrook and Women’s College Health Sciences Center in Ontario, Canada reported that the current way of administering chemotherapy may not take full advantage of the drugs’ ability to attack the blood vessel formation of tumors (angiogenesis).
Klement believes that the best way to inhibit angiogenesis is to administer lower doses of chemotherapy drugs on a more frequent basis-without periods of rest and for longer periods of time. This new treatment regimen is called “antiangiogenic scheduling” or “metronomic dosing.”
Klement believes that this new approach is promising, especially if angiogenesis-inhibiting drugs are added to the chemotherapy mix (combination chemotherapy). However, there is still skepticism among researchers as to the validity of Klement’s conclusions, especially given the lack of available evidence from human clinical trials.
Klement noted that a clinical trial is ongoing at the Hospital for Sick Children in Toronto to study the effect of metronomic chemotherapy in combination with cyclo-oxygenase 2 inhibitors to measure any improved efficacy against tumor blood vessel formation.
SOURCE:
2nd International Conference on Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention, June 2-6, 2001, North Falmouth, Massachusetts (As reported by Artemis, journal from Johns Hopkins)
metronomic chemotherapy per the National Cancer Institute
Treatment in which low doses of anticancer drugs are given on a continuous or frequent, regular schedule (such as daily or weekly), usually over a long time. Metronomic chemotherapy causes less severe side effects than standard chemotherapy. Giving low doses of chemotherapy may stop the growth of new blood vessels that tumors need to grow. Also called low-dose chemotherapy.
Metronomic Chemotherapy
Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has emerged. Such regimen involves the frequent administration of conventional chemotherapeutic agents at very low doses to target activated endothelial cells in tumors, the advantages of which include minimal adverse effects and a rare chance of developing acquired drug resistance. Previously it was thought that they act by targeting angiogenesis, but recently additional mechanisms have been discovered which has established metronomic chemotherapy as a type of multi-targeted therapy. The knowledge gained from the preclinical studies of metronomic chemotherapy, along with clinical experience, will help to design better therapeutic protocols against cancer. Detailed pharmacogenomic and pharmacoproteomic studies on tumor endothelial cells and large multi-centered clinical trials, integrating bio-marker analyzes, are needed to investigate and validate the best treatment combinations for each tumor type and patient population.
J Pharmacol Pharmacother. 2014 Jul-Sep; 5(3): 186–192.
doi: 10.4103/0976-500X.136098
Cancer Lett
. 2017 Aug 1;400:282-292.
doi: 10.1016/j.canlet.2017.01.040. Epub 2017 Feb 9.
Metronomic Chemotherapy and Immunotherapy in Cancer Treatment
Yu-Li Chen 1, Ming-Cheng Chang 2, Wen-Fang Cheng 3
PMID: 28189534 DOI: 10.1016/j.canlet.2017.01.040
Abstract
Systemic chemotherapy given at maximum tolerated doses (MTD) has been the mainstay of cancer treatment for more than half a century. In some chemosensitive diseases such as hematologic malignancies and solid tumors, MTD has led to complete remission and even cure. The combination of maintenance therapy and standard MTD also can generate good disease control; however, resistance to chemotherapy and disease metastasis still remain major obstacles to successful cancer treatment in the majority of advanced tumors. Metronomic chemotherapy, defined as frequent administration of chemotherapeutic agents at a non-toxic dose without extended rest periods, was originally designed to overcome drug resistance by shifting the therapeutic target from tumor cells to tumor endothelial cells. Metronomic chemotherapy also exerts anti-tumor effects on the immune system (immunomodulation) and tumor cells. The goal of immunotherapy is to enhance host anti-tumor immunities. Adding immunomodulators such as metronomic chemotherapy to immunotherapy can improve the clinical outcomes in a synergistic manner. Here, we review the anti-tumor mechanisms of metronomic chemotherapy and the preliminary research addressing the combination of immunotherapy and metronomic chemotherapy for cancer treatment in animal models and in a clinical setting.
An injectable microemulsion of a purified oil extracted from the seeds of the traditional Chinese medicinal herb Coix lacryma-jobi (Job’s tears), with potential antineoplastic activity. Although the exact mechanism of action is unknown, kanglaite exhibits an antineoplastic effect, potentially via interfering with the cell cycle and halting tumor cells in the G2/M phase, which may eventually inhibit mitosis and proliferation of cancer cells. Check for active clinical trials using this agent. (NCI Thesaurus)
Kanglaite (also known as Coix lacryma-jobi)
UPDATE January 2010 (from Michael McCulloch, LAc,MPH, PhD from Pine Street Foundation sent this:
There is a trial open in 9 states:
(http://clinicaltrials.gov/ct2/show/NCT00733850?term=kanglaite&rank=1) Ann’s NOTE: This trial ended in 2014/2015 with a statement that FDA would take a next step. ClinicalTrials.gov lists 8 studies, all in the USA have been ‘terminated’. Some are being done in China. (as of April 2020) Under the herb name we found 73 studies – mostly (unsurprisingly) in cell culture, called in vitro.
Excerpted from:
Ralph W. Moss, Ph.D. Weekly CancerDecisions.com
Newsletter #43 07/10/02
“FDA Approves Test of Traditional Chinese Medicine for Cancer
The US Food and Drug Administration (FDA) has approved a clinical trial of Kanglaite, a drug derived from an herb used in Traditional Chinese Medicine (TCM). The source of the drug is a tropical Asian grass called coix** (pronounced “coy”) or Job’s tears (lacryma-jobi), which is related to corn (maize).
The stalks of the coix plant contain white beadlike grains that, in addition to being eaten, are sometimes used to make necklaces.”
** I was perusing your website and noticed a little “misnomer” or incorrect writing of plant names. The plant species involved in the “Kangleite” research is a grass species with botanical name of Coix lacryma-jobi.
This is the Latin binomial name used by botanists worldwide, and it is the only stable and universally recognizable name for this plant. The common or vernacular names are often confusing or misleading; use them, but also use the botanical Latin name at the same time.
The name of the genus here is Coix. The name of the species is Coix lacryma-jobi. When written this way, these names should be italicized or underlined. There are at least four other species in the genus Coix. I thought this might help a bit.**
Bill B.
http://www.kanglaite-usa.com/, or
contact them at:
Kanglaite USA
Phone: 801-364-8904
Fax: 801-531-6558
Email: [email protected]
Metronomic Dosing: Chemotherapy
Giannoula Klement of Sunnybrook and Women’s College Health Sciences Center in Ontario, Canada reported that the current way of administering chemotherapy may not take full advantage of the drugs’ ability to attack the blood vessel formation of tumors (angiogenesis).
Klement believes that the best way to inhibit angiogenesis is to administer lower doses of chemotherapy drugs on a more frequent basis-without periods of rest and for longer periods of time. This new treatment regimen is called “antiangiogenic scheduling” or “metronomic dosing.”
Klement believes that this new approach is promising, especially if angiogenesis-inhibiting drugs are added to the chemotherapy mix (combination chemotherapy). However, there is still skepticism among researchers as to the validity of Klement’s conclusions, especially given the lack of available evidence from human clinical trials.
Klement noted that a clinical trial is ongoing at the Hospital for Sick Children in Toronto to study the effect of metronomic chemotherapy in combination with cyclo-oxygenase 2 inhibitors to measure any improved efficacy against tumor blood vessel formation.
SOURCE:
2nd International Conference on Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention, June 2-6, 2001, North Falmouth, Massachusetts (As reported by Artemis, journal from Johns Hopkins)
metronomic chemotherapy per the National Cancer Institute
Treatment in which low doses of anticancer drugs are given on a continuous or frequent, regular schedule (such as daily or weekly), usually over a long time. Metronomic chemotherapy causes less severe side effects than standard chemotherapy. Giving low doses of chemotherapy may stop the growth of new blood vessels that tumors need to grow. Also called low-dose chemotherapy.
Metronomic Chemotherapy
Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has emerged. Such regimen involves the frequent administration of conventional chemotherapeutic agents at very low doses to target activated endothelial cells in tumors, the advantages of which include minimal adverse effects and a rare chance of developing acquired drug resistance. Previously it was thought that they act by targeting angiogenesis, but recently additional mechanisms have been discovered which has established metronomic chemotherapy as a type of multi-targeted therapy. The knowledge gained from the preclinical studies of metronomic chemotherapy, along with clinical experience, will help to design better therapeutic protocols against cancer. Detailed pharmacogenomic and pharmacoproteomic studies on tumor endothelial cells and large multi-centered clinical trials, integrating bio-marker analyzes, are needed to investigate and validate the best treatment combinations for each tumor type and patient population.
J Pharmacol Pharmacother. 2014 Jul-Sep; 5(3): 186–192.
doi: 10.4103/0976-500X.136098
Cancer Lett
. 2017 Aug 1;400:282-292.
doi: 10.1016/j.canlet.2017.01.040. Epub 2017 Feb 9.
Metronomic Chemotherapy and Immunotherapy in Cancer Treatment
Yu-Li Chen 1, Ming-Cheng Chang 2, Wen-Fang Cheng 3
PMID: 28189534 DOI: 10.1016/j.canlet.2017.01.040
Abstract
Systemic chemotherapy given at maximum tolerated doses (MTD) has been the mainstay of cancer treatment for more than half a century. In some chemosensitive diseases such as hematologic malignancies and solid tumors, MTD has led to complete remission and even cure. The combination of maintenance therapy and standard MTD also can generate good disease control; however, resistance to chemotherapy and disease metastasis still remain major obstacles to successful cancer treatment in the majority of advanced tumors. Metronomic chemotherapy, defined as frequent administration of chemotherapeutic agents at a non-toxic dose without extended rest periods, was originally designed to overcome drug resistance by shifting the therapeutic target from tumor cells to tumor endothelial cells. Metronomic chemotherapy also exerts anti-tumor effects on the immune system (immunomodulation) and tumor cells. The goal of immunotherapy is to enhance host anti-tumor immunities. Adding immunomodulators such as metronomic chemotherapy to immunotherapy can improve the clinical outcomes in a synergistic manner. Here, we review the anti-tumor mechanisms of metronomic chemotherapy and the preliminary research addressing the combination of immunotherapy and metronomic chemotherapy for cancer treatment in animal models and in a clinical setting.